PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 709266

Minimum information needed by prescribers.

A Herxheimer·N D Lionel
View original source ↗Export metadata ↓

Abstract

The prescriber needs adequate and concise information about each product that he uses, to allow him to obtain optimal effects while minimising harm. Neither the present UK data sheets nor their equivalents in other countries have succeeded in providing such information clearly or completely. This paper develops the proposals on the arrangement of drug information made in the WHO report "The selection of essential drugs." Three sets of minimum information (on tetracycline, propranolol, and aspirin) which illustrate this approach were compared with the manufacturers' data sheets: the latter were incomplete. The information content of our proposals was worked out with a group of clinical pharmacologists, general practitioners, and specialists, and we suggest that this approach should be extended to other drugs.

Explore related subjects

AspirinDrug Information ServicesInformation ServicesPropranololTetracyclineJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Herxheimer, N D Lionel. 1978-10-21. Minimum information needed by prescribers.. https://doi.org/10.1136/bmj.2.6145.1129

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy.

OBJECTIVE: To review the available protocols for rapid desensitization of patients with aspirin hypersensitivity and apply the data for use in patients with cardiovascular disease who would benefit from the dual antiplatelet therapy. DATA SOURCES: A literature search was conducted via MEDLINE from 1966 to December 2006. Main search terms included: aspirin sensitivity, aspirin allergy, aspirin desensitization, aspirin-induced asthma, aspirin therapy, and aspirin intolerance syndrome. STUDY SELECTION AND DATA EXTRACTION: Articles describing rapid aspirin desensitization protocols were selected for review. Literature pertaining to aspirin hypersensitivity, drug desensitization, and the use of aspirin and dual antiplatelet therapy was also examined. Three rapid desensitization protocols were identified and evaluated. DATA SYNTHESIS: While landmark studies demonstrated that dual antiplatelet therapy with aspirin and clopidogrel significantly reduces mortality and morbidity in acute coronary syndromes and coronary stenting, patients with aspirin hypersensitivity are frequently managed with clopidogrel alone with no supporting data. Approximately 10% of the population experiences hypersensitivity to aspirin, which can manifest as asthma exacerbations, rhinorrhea, angioedema, urticaria, and anaphylaxis. The hypersensitivity reaction is mediated through aspirin-directed antibodies or by excessive leukotriene production. The desensitization process involved depletion of these mediators, as well as down-regulation of leukotriene receptors. Two groups of investigators developed rapid protocols to desensitize patients with aspirin hypersensitivity safely and effectively. The rapid protocol developed by Wong provides benefits over other protocols with its low starting dose and completion in less than 3 hours, low incidence of adverse effects, and high success rate in aspirin desensitization. CONCLUSIONS: The Wong protocol is an attractive option for the rapid desensitization of patients requiring dual antiplatelet therapy with aspirin and clopidogrel in the perimyocardial infarction period.

Aspirin↗